ENTITY
Simcere Pharmaceutical

Simcere Pharmaceutical (2096 HK)

111
Analysis
Health Care • China
Simcere Pharmaceutical Group is an innovation and R&D-driven pharmaceutical company engaged in the research, development, manufacturing, and sale of pharmaceutical products. It focuses on therapeutic areas such as oncology, central nervous system diseases, autoimmune diseases, and anti-infection, with key products including Sanbexin, Endostar, and Bicun. The company was founded in 1995 and is headquartered in Nanjing, China.
more
•30 Jan 2026 11:33

Hong Kong Buybacks Weekly (Jan 30th): Sunny Optical, Geely Automobile, Country Garden Services

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Sunny Optical,...

Logo
204 Views
Share
•23 Jan 2026 10:58

Hong Kong Buybacks Weekly (Jan 23rd): Xiaomi, Sunny Optical, Geely Automobile

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Xiaomi (1810 HK),...

Logo
198 Views
Share
•20 Jan 2026 09:50

Simcere Zaiming (先声再明) Pre-IPO: A Credible Oncology-Focused Biopharma Spin-Off

​Biopharma spin-off Simcere Zaiming seeks to raise $100 million via a Hong Kong listing with MS and CICC as sponsors. We examine its products,...

Logo
406 Views
Share
•18 Jan 2026 10:05

HK Connect Flows Weekly (Jan 16th): Tencent, Kuaishou, China Mobile, Xiaomi, CCB, China Life

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Tencent (700 HK), Kuaishou (1024 HK), China Mobile (941...

Logo
464 Views
Share
bullish•Rio Tinto Ltd
•18 Jan 2026 06:30

Last Week In Event SPACE: Rio/Glencore, Simcere Pharma, Mandom Corp, Qube, Jinke Smart

It’s Sunday! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed during the...

Logo
434 Views
Share
x